1. In Vivo
  2. >>Leadership

New AdvaMed Chair Lobo: Devices Has A Good Story To Tell

Nadim Yared Will Be A Hard Act To Follow For New AdvaMed Chair Kevin Lobo

 
• By Ashley Yeo

A whirlwind two-year stint as chair of the US medtech industry association, AdvaMed, came to end this month for CVRx’e energetic CEO Nadim Yared. Incoming chair, Stryker’s Kevin Lobo, comes from an altogether much larger concern, but he will continue Yared’s legacy of supporting SMEs, as well as bringing his own agenda to the role.

Stryker CEO Kevin Lobo
Kevin Lobo, CEO of Stryker and new AdvaMed chair • Source: Advamed/Stryker

CVRX CEO Nadim Yared will be a hard act to follow as AdvaMed chair, as his list of accomplishments over the past two years, as well as his ability to maintain the spotlight on the medtech industry in the US and beyond, have shown. In Kevin Lobo, CEO of Stryker Corp., the industry has a leader who will continue to push back the boundaries for SMEs, as well as developing his own agenda points.

Lobo’s two-year tenure was announced on March 27, and he knows that the 2012 medical device excise tax will continue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

More from In Vivo

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.